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The choroid comprises part of the uveal tract and is the most vascular layer of the eye, lying between the retina and the 
sclera. Lung cancer is the most common cause of choroidal 
metastases in men and vision loss occurs via accumulation of 
subretinal fluid that can lead to retinal detachment.1 Herein, 
we present three cases of patients with choroidal metastases 
with different molecular characteristics who had improvement 
in vision with systemic treatment with or without radiotherapy 
(Table 1).
CASE 1
A 36-year-old, nonsmoking man presented with right-
eye vision loss. Ophthalmologic exam revealed a choroi-
dal lesion. Magnetic resonance imaging (MRI) of the brain 
showed a right choroidal mass (Fig. 1). Body computed 
tomography (CT) revealed a left upper-lobe lung mass, as well 
as bone and liver metastases. Lung adenocarcinoma was diag-
nosed on liver biopsy.
The patient received stereotactic radiation to the choroidal 
lesion and was started on cisplatin/pemetrexed/bevacizumab, 
with significant improvement in vision and overall disease 
burden. He was able to work fulltime and remained physically 
active. Molecular analysis showed an EGFR exon 20 insertion 
and an E542K PIK3CA mutation. He had systemic progression 
12 months later and was placed on a clinical trial. Unfortunately, 
he experienced continued weight loss and decline in his func-
tional status, consistent with a lack of response to therapy. After 
2 months, he developed increased confusion and seizures. MRI 
of the brain showed hydrocephalus and diffuse leptomeningeal 
disease. He then began home hospice.
CASE 2
A 60-year-old man presented with cough and short-
ness of breath. CT revealed a left lung mass, pulmonary 
nodules, mediastinal lymphadenopathy, pleural effusions, 
and bone lesions. MRI showed diffuse brain metastases 
less than 5 mm in size. Lung adenocarcinoma was diag-
nosed on pleural fluid cytology. Given the symptomatic 
pulmonary disease, carboplatin and pemetrexed were given 
without waiting for mutation status or brain irradiation, 
and bevacizumab was deferred in the setting of untreated 
brain metastases. Subsequent molecular testing showed 
an EGFR L858R activating mutation. After three cycles 
of chemotherapy, he had a systemic partial response, but 
soon after, presented to the emergency department with 
right-eye vision loss. Ophthalmologic exam showed right-
eye choroidal metastases. The patient received whole-brain 
radiotherapy with anterior fields incorporating the choroi-
dal region. His vision returned to normal after radiother-
apy. He then received carboplatin/pemetrexed/bevacizumab 
for four cycles followed by pemetrexed/bevacizumab until 
slight systemic progression after 10 maintenance cycles. 
He was next started on erlotinib with continued resolution 
of visual symptoms and no evidence of recurrent choroid 
metastases on eye exam at the time of this report, more than 
19+ months into therapy.
CASE 3
A 42-year-old nonsmoking man presented with left-eye 
vision loss. Eye exam showed a choroidal metastasis (Fig. 2) 
and MRI was negative for intracranial disease. Body CT 
showed a left-lower lobe lung mass, bony metastases, and 
mediastinal adenopathy. Mediastinal node biopsy confirmed 
lung adenocarcinoma with fluorescent in situ hybridization 
positive for an ALK translocation.
The patient was started on cisplatin/pemetrexed/
bevacizumab followed by pemetrexed/bevacizumab 
continuation maintenance with improvement in vision 
until progression, which was noted 16 months later when 
he developed recurrence of vision loss, bilateral choroidal 
metastases, new brain metastases, as well as diffuse brain and 
spine leptomeningeal disease. He was treated with stereotactic 
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radiation for his central nervous system disease and afterward 
received crizotinib. After progression on crizotinib 5 months 
later, he received irinotecan briefly and then was transitioned 
to hospice.
DISCUSSION
Non–small-cell lung cancer with heterogeneous molec-
ular characteristics can manifest as choroidal metastases. Both 
systemic chemotherapy and local radiotherapy can improve 
vision. Treatment including pemetrexed and bevacizumab for 
systemic therapy contributed to improved vision in all three 
patients, one of whom had improved, long-term improvement 
in vision without radiotherapy. The choroid is highly vascu-
lar and vascular endothelial growth factor inhibition with 
both systemic and intravitreal bevacizumab have been noted 
to improve vision loss from choroidal metastases.2,3 Because 
pemetrexed also has central nervous system activity, it may 
also be useful in treating choroid metastases, particularly in 
patients  with ALK+ tumors who may derive increased ben-
efit from pemetrexed.4,5 Two of three patients recurred with 
leptomeningeal disease, highlighting this as a possible pattern 
of spread from initial choroid disease to eventual progression 
within the leptomeninges.
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TABLE 1.  Summary of Choroidal Metastases Cases
Case Age (yr) Genetic Alteration CNS Disease Therapy Duration of Vision 
Improvement (mo)
1 36 EGFR Exon 20 Insertion/ 
PIK3CA E542K
Right-eye choroid Cisplatin, pemetrexed, bevacizumab, 
stereotactic radiation,
15
2 60 EGFR L858R Right-eye choroid, multiple 
intracranial brain metastases
Carboplatin, pemetrexed, bevacizumab 
(intercurrent whole-brain radiation), then 
erlotinib
19+
3 42 ALK translocation Left-eye choroid Cisplatin, pemetrexed, bevacizumab, 
crizotinib, irinotecan
16
FIGURE 1.  Right-eye choroidal metastasis on magnetic 
resonance imaging (arrow).
FIGURE 2.  Choroid metastasis from non–small-cell lung 
cancer on ophthalmologic examination (arrows).
